Abstract
Breast cancer constitutes the second most common cause of BMs with a higher prevalence in patients with triple-negative and HER2-positive mBC. T-DXd, an antibody-drug conjugate targeting HER2, has shown promising efficacy in patients with HER2-overexpressing mBC and treated asymptomatic BMs. We aimed to analyze the efficacy of T-DXd in patients with BMs and mBC according to HER2 status in patients from DAISY trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
